Skip to main content
. 2023 Apr 12;115(7):796–804. doi: 10.1093/jnci/djad061

Figure 3.

Figure 3.

Overall survival stratified by irAEs onset in patients who switched from CD to ED (A) and in patients treated upfront with ED ICIs (B). Overall survival was calculated since start of ED treatment. Landmark method was used to correct for immortal time bias (all patients who died before 3 months were excluded from the analysis). CD = canonical interval dosing; ED = extended interval dosing; ICI = immune checkpoint inhibitors; irAEs = immune-related adverse events.